Therapeutic Efficacy of Aldoxorubicin in an Intracranial Xenograft Mouse Model of Human Glioblastoma()()

Glioblastoma multiforme (GBM) is the most aggressive primary brain tumor with a median survival of 12 to 15 months after diagnosis. Acquired chemoresistance, high systemic toxicity, and low penetration of the blood brain barrier by many anticancer drugs contribute to the failure of anti-GBM therapie...

Descripción completa

Detalles Bibliográficos
Autores principales: Marrero, Luis, Wyczechowska, Dorota, Musto, Alberto E., Wilk, Anna, Vashistha, Himanshu, Zapata, Adriana, Walker, Chelsey, Velasco-Gonzalez, Cruz, Parsons, Christopher, Wieland, Scott, Levitt, Daniel, Reiss, Krzysztof, Prakash, Om
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Neoplasia Press 2014
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4212249/
https://www.ncbi.nlm.nih.gov/pubmed/25379024
http://dx.doi.org/10.1016/j.neo.2014.08.015

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4212249/
https://www.ncbi.nlm.nih.gov/pubmed/25379024
http://dx.doi.org/10.1016/j.neo.2014.08.015

Ejemplares similares